You position:
Home
/
/
Pluslife Biotech Prepares the Northern Hemisphere for a Flu-COVID-19 ‘Twindemic’

Pluslife Biotech Prepares the Northern Hemisphere for a Flu-COVID-19 ‘Twindemic’

  • Categories:News & Events
  • Author:PL_2
  • Origin:
  • Time of issue:2022-11-25 11:31
  • Views:

(Summary description)

Pluslife Biotech Prepares the Northern Hemisphere for a Flu-COVID-19 ‘Twindemic’

(Summary description)

  • Categories:News & Events
  • Author:PL_2
  • Origin:
  • Time of issue:2022-11-25 11:31
  • Views:
Information

Pluslife Biotech is working diligently in preparing the Northern Hemisphere for the incoming 2022-2023 Flu Season which typically starts in the fall and ends in the spring of next year. Having the first ‘unlocked’ flu season in the Southern Hemisphere concluded the worst during the COVID pandemic era, the Northern Hemisphere should be more guarded to monitor the co-circulation of Influenza and COVID-19 viruses this winter.  

 

As a matter of fact, influenza activity in the northern hemisphere has increased at varying levels among regions. In the US, the outpatient rate of respiratory illness is above the baseline, not to mention a noticeably high flu hospitalization rate that hasn’t been reached in more than a decade. Other common respiratory viruses, such as respiratory syncytial virus (RSV), which is experiencing 10 times higher hospitalization rates than usual. The seasonal diseases have hit earlier and harder than usual and placed a huge strain on the healthcare systems nationwide.

 

In Europe, overall influenza activity remains relatively low and most confirmed cases are rounded up in Germany, France, Portugal, Italy, Spain and the United Kingdom. However, in comparison to the influenza trend last year, the flu season of 2022 has arrived earlier with a higher activity rate, which is coincident with the situation in America. Experts expect continuing surging influenza cases will create greater stress on the healthcare system.  

 

 

To bolster the preparedness for Flu-COVID-19 ‘Twindemic’, WHO issued the interim guidance “End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance”, underpinning the importance of diagnoses and treatments to prevent severe disease and hospitalizations associated with COVID-19 and influenza in northern hemisphere countries. To support the initiatives of WHO and other healthcare authorities, Pluslife is partnering with medical providers to have infrastructures, hospitals, clinics and testing centers prepared for respiratory disease monitoring. 

 

The Pluslife Winter Collection

The Pluslife Winter Special features products that help medical providers examine infections/co-infections and identify the exact causes of sickness for medical treatments given the symptoms are similar between COVID-19, Influenza, and RSV. 

 

Pluslife POC Molecular Solution

 

Key Features and Benefits

 

 

Test Performances

Ref.

  1. https://www.cdc.gov/flu/weekly/index.htm 
  2. https://www.cdc.gov/flu/weekly/usmap.htm 
  3. https://edition.cnn.com/2022/11/18/health/flu-rsv-spread-emergency-response/index.html 
  4. https://www.ecdc.europa.eu/en/publications-data/weekly-influenza-update-week-45-november-2022 
  5. https://www.politico.eu/sponsored-content/preparing-for-the-uks-first-unlocked-winter/
  6. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00503-5/fulltext 

Related News

There is currently no information to display
Please add data record on website background.

Tel: +86-2031607074
E-mail: market@pluslife.com

Add: 3F-Block E, Runhui Science & Technology Park, No. 18 Shenzhou RD, Huangpu District, Guangzhou, Guangdong, China

PLUSLIFE BIOTECH

Monday - Friday, 08:00 -20:00

Copyright © 2021 Guangzhou Pluslife Biotech Co., Ltd.  粤ICP备19038432号  Powered by www.300.cn